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RESUMO 
 
 As células neoplásicas humanas são capazes de atingir a imortalidade. Os 
mecanismos através dos quais isto é conseguido baseiam-se na capacidade destas 
células de contrariar o encurtamento dos telómeros. Estes são estruturas nucleoproteicas 
que protegem o término dos cromossomas e consistem em sequências repetitivas 
(TTAGGG)n ricas em guanina. A telomerase é uma enzima transcriptase reversa que 
contém tanto um componente catalítico proteico como um molde de RNA e é a principal 
responsável pelo alongamento dos telómeros e células somáticas adultas humanas 
reprimem normalmente a expressão desta enzima. Porém, aproximadamente 90% das 
células neoplásicas humanas voltam a expressá-la com o objectivo de manter o 
alongamento dos telómeros, sendo que mutações no promotor da telomerase são a 
causa genética conhecida mais frequente. Por outro lado 10 a 15% dos cancros não 
apresentam actividade telomerase detectável e uma parte desses atinge a imortalidade 
através de um mecanismo de elongação de telómeros independente da telomerase, o 
ALT (Alternative Lenghtening of Telomeres), que depende do mecanismo de reparação 
de DNA HR (Homologous Recombination). Mutações inactivadoras foram identificadas 
nas proteínas ATRX e DAXX e no complexo Histona H3.3 em várias células tumorais 
consideradas ALT-positivas, maioritariamente em tumores endócrinos do pâncreas, 
glioblastomas multiformes e oligodendrogliomas. Além disso, o fenótipo ALT é 
caracterizado pela presença de telómeros de tamanhos heterogéneos, APBs (ALT-
associated promyelocytic leukaemia bodies) e recombinação telomérica com presença de 
repetições teloméricas extra-cromossomais (ECTRs).  
 O recentemente descoberto sistema de defesa bacteriano CRISPR/Cas9 foi 
rapidamente convertido numa ferramenta importante na área da engenharia genética, 
tornando-se imediatamente numa das mais vantajosas técnicas neste campo da Ciência. 
Consiste na utilização de uma endonuclease Cas9 e um RNA guia (sgRNA) específico 
para um gene ou loci genómico. Uma vez co-expressos, formam um complexo ribo-
proteico que permite que a Cas9 ligue ao alvo genómico e o corte,resultando numa dupla 
quebra do DNA. Dependendo do mecanismo de reparação de DNA activado em 
resposta, a técnica permite fazer silenciamento (Knock-Out) de um gene ou edição do 
genoma. Recentemente, várias modificações à enzima Cas9 permitiram a extensão das 
aplicações da técnica. A construção de uma Cas9 desactivada – dCas9 – (através da 
mutação dos domínios catalíticos) que pode ser fundida com outras moléculas como 
factores de transcrição ou proteínas fluorescentes potenciou parte dessas novas 
aplicações. Neste trabalho explorámos a possibilidade de usar a dCas9 fundida com a 
proteína GFP e um sgRNA que guiasse este complexo para repetições teloméricas, com 
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o objectivo de visualizar e comparar o tamanho dos telómeros, numa linha celular  de 
tumor neuroendócrino do pâncreas (Bon), in vivo. Para isso, produzimos lentivírus 
contendo o DNA dos vectores de interesse e infectámos as  referidas células com os 
mesmos. Conseguimos assim visualizar a fluorescência característica da infeção com 
dCas9-EGFP mas, como a eficiência da transdução com os lentivírus foi aparentemente 
muito baixa, não foi possível fazer a seleção dessas células (para obter apenas aquelas 
que expressam estavelmente esse DNA). Por essa razão, foi também impossível infectar 
com sucesso as células com os sgRNAs e observar a pretendida fluorescência específica 
de telómeros. Num futuro próximo pretendemos, no entanto, optimizar o protocolo e 
atingir o objectivo de estabelecer uma linha celular expressando estavelmente dCas9-
EGFP, produzindo assim a ferramenta pretendida. 
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ABSTRACT 
 
 Human cancer cells are capable of achieving immortality. The mechanisms by 
which they achieve it partially rely in being able to counteract the shortening of their 
telomeres, which are DNA-protein structures that protect chromosome ends and consist of 
arrays of guanine-rich (G-rich) repeats (TTAGGG)n, Telomerase is a reverse transcriptase 
enzyme with both a protein catalytic component and a RNA template and is the main 
responsible for telomere elongation. Human adult somatic cells usually repress the 
telomerase enzyme expression. However, up to 90% of human cancers cells de-repress 
its expression to maintain telomere length, telomerase promoter mutations being the 
known most frequently found event. On the other hand, 10% to 15% of cancers do not 
present detectable telomerase activity and a part of those achieves immortalization via a 
telomerase-independent mechanism of telomere lengthening, the alternative lengthening 
of telomeres (ALT), which depends on a homologous recombination (HR) DNA-repair 
mechanism. Inactivating mutations were identified in the ATRX, DAXX and Histone H3.3 
complex in ALT-positive tumor cells, mainly in pancreatic endocrine tumors, glioblastoma 
multiforme and oligodendrogliomas. Besides that, the ALT phenotype is characterized by 
the presence of heterogeneous telomere lengths, ALT-associated promyelocytic 
leukaemia bodies (APBs) and telomere recombination with the presence of 
extrachromosomal (linear and circular) telomeric repeats (ECTRs). 
 The recently discovered bacterial defence system CRISPR/Cas9 was readily 
converted into a tool in the area of genome engineering, turning immediately into one of 
the most advantageous techniques to be used in this field of science. It consists in the 
presence of a Cas9 endonuclease and a guide RNA (sgRNA) targeting a specific 
gene/genomic loci. Once co-expressed, they form a riboprotein complex allowing Cas9 to 
ligate the target and perform cleavage, resulting in a DNA Double Strand Break. 
Depending on the mechanisms of DNA repair that is then activated, this technique allows 
performing KO’s or genome editing. More recently, various modifications to the Cas9 
enzyme have extended its applications. The generation of a deactivated dCas9 (by 
mutationally inactivating its two nuclease domains) that could be fused to other molecules 
such as transcriptions factors or fluorescent proteins made it clear that it could be used for 
various purposes.. Altogether, this stressed the possibility of using dCas9 fused to the 
GFP protein and a sgRNA guiding to a telomeric repeat sequence to visualize and 
compare the telomeric lengths and their observable appearance in Bon pancreatic 
neuroendocrine tumor cells, in vivo. In this project, we produced lentivirus harbouring the 
necessary vectors and transduced the interest cells with those. We were able to confirm 
the characteristic fluorescence of the Tet3G/dCas9 infection but, as the transduction 
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efficiency was low, we could not select cells stably expressing the vectors. Therefore, it 
was impossible to successfully transduce the cells with the sgRNAs and produce the 
telomere-specific fluorescence that we aimed to see. In the near future, we intend to 
optimize this protocol until we reach our goal of establishing a clonal cell line stably 
expressing dCas9-EGFP. 
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INTRODUCTION 
 
 Through life, human beings experience the effects of ageing, ultimately leading to 
death. However, even within mortal beings, there are cells that can achieve immortality: 
the cancer cells. The mechanisms by which these cells become immortal partially rely in 
being capable of counteracting the shortening of their telomeres, the universal biological 
clock.  
Telomeres and immortalization 
   
 In the first half of the 20th century, it was discovered that the chromosomes, 
localized in the cell nucleus, carry the genetic information (Thomas H. Morgan; Nobel 
Prize in Physiology or Medicine 1933). A decade later, Herman Muller and Barbara 
McClintock discovered that broken chromosomes were unstable, i.e. prone to 
rearrangements and/or fusions [1, 2]. However, chromosome ends seemed to be 
protected from such events. The special nature of chromosome ends were described and 
they were named telomeres (from the Greek words “telos” (end) and “meros” 
(part)) by Muller for the first time [1]. Currently, it is known that telomeres are DNA-protein 
structures that protect chromosome ends and consist of arrays of guanine-rich (G-rich) 
repeats (TTAGGG)n, in vertebrates.  
 The discovery of DNA polymerases was of extreme importance in order to 
understand chromosome dynamics. They were demonstrated to be dependent on a 
primer for enzyme coupling in order to replicate DNA (Severo Ochoa and Arthur 
Kornberg; Nobel Prize in Physiology or Medicine 1959) and, in 1972, James Watson 
observed that it was theoretically impossible that both strands could be synthesized in 
these conditions [3]. This observation was denominated the end-replication problem 
(Figure 1). By this time, Leonard Hayflick had introduced two novel concepts in science 
(“The Hayflick Limit”): normal cells in culture are not immortal and there is a memory that 
allows cells to undergo a specific number of population doublings (what we call nowadays 
the biological clock) [4]. In 1973, Alexsei Olovnikov reported that newly formed DNA would 
have an incomplete strand at some point in time and made the connection with the facts 
reported by Hayflick, hypothesizing that the incomplete replication could be the basis for 
the chromosome shortening observed in cultured cells overtime, culminating in reduced 
viability [5].  
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Figure 1 – The end-replication problem. Copying of the lagging strand of a DNA molecule 
by the DNA polymerase enzyme occurs gradually. The process is dependent on an RNA 
primer that is degraded immediately after. The gap is filled and ligated to produce a new 
semi conserved DNA molecule. DNA polymerases are not able to fill the gap in the end of 
the chromosomes. This results in these becoming shorter upon each round of replication. 
Adapted from “The 2009 Nobel Prize in Physiology or Medicine – Advanced Information”. 
Nobelprize.org. Nobel Media AB 2014. Web. 13 Jun 2016.  
http://www.nobelprize.org/nobel_prizes/medicine/laureates/2009/advanced.html 
 
  
 By the late 70s, Jack Szostak was working on the unravelling of the mechanisms 
occurring in the homologous recombination process, in yeast. He found that the ends of 
linear plasmid DNA molecules introduced into yeast cells were highly recombinogenic. 
This, as he assumed, would lead to rearrangements or interaction with homologous 
chromosomal DNA and integration. However, the observation was made that long-term 
maintenance was not possible [6]. These findings were in line with the early observations 
by Muller and McClintock (mentioned above) that broken chromosomes are highly 
unstable. 
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 Elizabeth Blackburn and Jack Szostak attended the same Gordon conference in 
1980, where they discussed the astonishing properties of telomeres and, finally, decided 
to collaborate. They investigated if adding Tetrahymena chromosome end repeat DNA 
sequences to linear yeast plasmids could stabilize the ends to allow replication. The most 
striking conclusion from these experiments was that the evolutionarily conversed 
functional properties of the Tetrahymena rDNA end sequences provided chromosomal 
stability. Also, there were functionally similar sequences in yeast. All this thus allowed to 
deduct that such end sequences corresponded to functional telomeres [7]. 
 At this point, Carol Greider had joined Elizabeth Blackburn laboratory and they 
started investigating the mechanisms underlying the synthesis of these telomeric 
structures. Greider developed a biochemical assay using Tetrahymena extracts, where 
synthetic DNA oligonucleotides complementary to the telomeric repeats were used as a 
primer. Using this technique, she showed addition of TTGGGG repeats in vitro, leading to 
the notion that there was enzymatic activity present in these cell extracts [8]. In their 
following work, Greider and Blackburn finally presented the term telomerase and began 
demonstrating that this enzyme is a ribonucleoprotein dependent on both its protein and 
RNA components. About the RNA component, whose function was still not fully 
understood at the time, the two scientists wrote: “It is tempting to speculate that the RNA 
component might be involved in determining the sequence of the telomeric repeats that 
are synthesized and/or the specific primer recognition. If the RNA of telomerase contains 
the sequence CCCCAA, this sequence could act as an internal guide sequence”. As 
reported by Greider and Blackburn in the following year, the RNA component was indeed 
found to contain this template sequence. Also, the two scientists interestingly found that 
blocking of this motif availability compromised telomerase enzymatic activity [9]. The role 
of the CAACCCCAA RNA sequence as a template for telomere synthesis was confirmed 
when Blackburn’s group showed that mutations in this sequence resulted in 
corresponding alterations in the DNA sequence being synthesized [10]. This data allowed 
to confirm the role of telomerase as a reverse transcriptase with a protein catalytic 
component as well as a RNA template for telomere elongation. A new model for the 
elongation of telomeres was thus presented by Greider and Blackburn (Figure 2): First, 
telomerase recognizes Tetrahymena chromosome ends containing a 13-base 
overhanging TTGGGG sequence, leading to hybridization between the complementary 
nucleotides. TTG nucleotides are then added stepwise and a translocation of the 
telomerase enzyme occurs as it is relocated to the 3’end of the TTGGGG strand such that 
the 3’ TTG nucleotides are hybridized to the enymatic RNA component. Finally elongation 
occurs, copying the template sequence to complete the TTGGGGTTGG sequence. This 
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mechanisms explains how oligonucleotides with 3’ends terminating at any nucleotide with 
the 
sequence TTGGGG are elongated to yield perfect tandem repeats of (TTGGGG)n  [9]. 
 
Figure 2 – A model for telomere elongation. Adapted from Greider and Blackburn, 1989 
[9].  
 
 Human adult somatic cells usually repress the telomerase enzyme expression, 
although it continues to be expressed in proliferative cells (germ cells and tissue stem 
cells) [11]. Up to 90% of human cancers cells de-repress its expression to maintain 
telomere length (critical for tumor genomic stability and immortality) [11], telomerase 
promoter mutations being the most frequently found known event [12]. However, 10% to 
15% of cancers do not present detectable telomerase activity. A subset of those 
(approximately 5%) achieves immortalization via a telomerase-independent mechanism of 
telomere lengthening, the so-called alternative lengthening of telomeres (ALT) that, as will 
be further addressed, depends on a homologous recombination (HR) DNA-repair 
mechanism to maintain telomere length [13].  
Cancers that have a mesenchymal origin are reported to activate ALT more 
frequently, while epithelial cancers rely more frequently in telomerase reactivation/re-
expression [13, 14]. As mesenchymal stem cells are known to express minimal or no 
detectable amounts of telomerase [15], this may predispose cells from this lineage to 
depend on ALT activation more frequently. Genome mapping by the somatic cell 
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hybridization technique had already demonstrated that ALT activation occurred through 
the loss of one or more repressor molecules present in normal somatic telomerase 
positive cells [16]. More recently, with the appearance of mass genome sequencing 
techniques, inactivating mutations were identified in the ATRX, DAXX and Histone H3.3 
complex in ALT-positive tumor cells, mainly in pancreatic endocrine tumors [17], 
glioblastoma multiforme and oligodendrogliomas [18].  Moreover, it has been pointed that 
the appearance of the ALT phenotype can, in part, be a consequence of ATRX 
inactivating mutations [19]. 
Alternative Lengthening of Telomeres 
 
 In cancers where no detectable telomerase activity is found, telomere length is 
frequently assured by an homologous recombination (HR) mechanism, ALT [13].  The first 
observation of this phenomenon was a telomerase knockout model in yeast (even-short 
telomeres 1 - EST1), where it was discovered that this cells could maintain telomere 
length without telomerase activity. However, if a double knockout for RAD52 protein was 
performed, the cells did not survive [20]. RAD52 is a critical protein for the double strand 
break repair by HR and these experiments enlightened the central basis behind ALT 
mechanism. Moreover, studies using exogenous DNA integration into telomeric regions 
with tagged DNA were able to demonstrate that, in cells bearing the ALT phenotype, 
transference from one telomere to another occurs, subsequent to cell divisions [21]. It is 
important to refer that the ALT phenotype is characterized by the presence of: 
heterogeneous telomere lengths; ALT-associated promyelocytic leukaemia bodies 
(APBs), that differ from common promyelocytic leukaemia (PML) bodies found in other cell 
types by the inclusion of telomeric DNA and numerous specific recombination factors [22]; 
and telomere recombination with the presence of extrachromosomal (linear and circular) 
telomeric repeats (ECTRs) [23]. These features are consistent with hyperactive HR and 
the extrachromosomal telomeric DNA has been proposed to serve as a template for the 
extension of telomeres [24]. 
  Mechanisms for ALT 
 Various proposed models describe how telomeres are maintained and extended 
without telomerase enzymatic activity (Figure 3) [25]. The first (Figure 3A) represents a 
model based in break-induced repair (BIR), a mechanism where DNA is synthetized away 
from a break site using HR donor template that, in this case, is telomeric DNA. The 
models 1 and 2 in Figure 3A differ in the timing of the lagging strand and, in both, there is 
loss of material in recipient telomeres. The model 3 represents a unidirectional replication 
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fork that will require a Holliday junction in the end of the process and, in this case, both 
donor and recipient telomeres will be semi-conserved [26]. Unequal telomeric sister 
chromatid exchange (T-SCE) has also been suggested as a mechanism for ALT (Figure 
3B). This is supported by the fact that T-SCE is elevated in ALT+ cells as measured by 
CO-FISH [27]. Finally, the recurrent presence of linear and circular extrachromosomal 
telomere DNA (ECTRs) in ALT cells suggests that these molecules can be used as 
templates for HR-driven telomere elongation or simply undergo rolling-circle replication 
(Figure 3C) [25]. 
Figure 3 - Theoretical models for ALT mechanism. A) Break-induced replication loss from 
the donor telomere (1 and 2 without loss from the donor telomere). In model 3 there is a 
unidirectional replication fork with semi-conservative replication of the telomeres. B) 
Unequal telomeric sister chromatid exchange (T-SCE) model. C) Rolling circle and t-circle 
formation after t-loop resolution providing a linear double strand break for subsequent HR-
mediated activation into the homologous templates. Adapted from Durant, ST 2012 [25]. 
  ATRX protein role in ALT 
 ATRX gene is localized in chromosome Xq21.1 and it encompasses 37 exons [28, 
29]. This gene encodes a chromatin remodeler which is a 280 kDa protein that includes 
an unusual N-terminal plant homeodomain (PHD), designated the ATRX-DNMT3-
DNMT3L (ADD) domain [30-32]. At the C terminus it presents seven helicase subdomains 
that confer ATPase activity and identify ATRX as a Snf2 family member of chromatin-
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associated proteins [33]. As previously mentioned, it is known that ATRX, in collaboration 
with its partner DAXX, functions as a complex for the deposition of the histone variant 
H3.3 into telomeric and pericentromeric chromatin. DAXX is a highly specific histone 
chaperone that is able to discriminate H3.3 from the other major histone variants, whereas 
ATRX is involved in targeting DAXX to repetitive sequences enhancing histone 
deposition[34, 35]. 
 Immunofluorescence studies have demonstrated that ATRX has a preference for 
binding within PML bodies and also to repetitive heterochromatic regions such as 
ribossomal DNA (rDNA), telomeric and pericentric DNA repeats [36-38]. The localization 
of ATRX to heterochromatin involves the interaction with the heterochromatin protein 1 
(HP1) [39-41]. Also, targeting of ATRX to heterochromatin is dependent on its interaction 
with histone H3 trimethylated Lys9 (H3K9m3) and unmodified Lys4 (H3 K4m0) [42]. An 
hypothesis is that HP1 might serve as a protein scaffold, facilitating the recruitment of 
ATRX to the heterochromatin through binding of H3K9me3 via its N-terminal 
chromodomains [42, 43] (Figure 2). Still, this recruitment seems to be of extreme 
complexity and rely on multiple interactions between effector proteins and chromatin.  
 Figure 4: A proposed theoretical mechanism for ATRX/DAXX chromatin landscaping: 
ATRX binds to histone H3 at heterochromatin through interaction of its ADD domain with a 
H3 N-terminal tail, trimethylated at Lys9 (H3K9me3) and unmodified at Lys4 (H3K4me0). 
HP1 also recognizes H3K9me3, boosting this recruitment. Once in its target site, ATRX, in 
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combination with DAXX, facilitates the deposition of the histone variant H3.3. Adapted 
from Clynes et al. 2013 [43]. 
 
 It is reported that heterochromatic regions are prone to DNA damage in the 
absence of the ATRX protein [44, 45]. This could mean that it plays a role in one of the 
two DNA DSB (Double Strand Break) repair mechanisms (Non Homologous End Joining – 
NHEJ in post mitotic cells; Homologous Recombination - HR in proliferative ones). 
However, exposing ATRX-KO cells to irradiation led to the suggestion that the protein is 
not required for repair of induced DSBs and, therefore, its role might be of protecting cells 
from replicative stress instead of repairing it [45, 46]. Interestingly, and in contrast with the 
latter, a more recent approach to this question by Koschmann, C. et al., brought new 
insights regarding the role of ATRX in DNA-repair pathways. The authors used an animal 
model of ATRX-deficient glioblastoma to uncover the impact of this protein loss in tumor 
proliferation and loss of genetic stability. They found out that the reduction of ATRX levels 
impaired NHEJ pathway, as transfection with a DNA-damaged GFP (designed to be 
restored by NHEJ) simultaneous to ATRX silencing reduced NHEJ function by 50% [47]. 
These findings suggest that a relative increase in HR in relation to NHEJ in ATRX-
deficient gliomas may be supportive of ALT. Also, this data is explicative of the genetic 
instability, and altered DNA damage response in ALT cell lines [44, 46, 47], besides 
providing a molecular target that can be explored to design new targeted therapies 
regarding ALT-positive gliomas.  
 Telomeres composition of repetitive DNA with an high content of guanine and 
cytosine residues leads to the formation of secondary DNA structures, the G4-DNA [48]. 
These are known to form obstacles (like bulky DNA adducts) to multiple nuclear 
processes including DNA replication and transcription. A large proportion of ATRX target 
sites are predicted to adopt non-B DNA structures like these G-quadruplexes [49], leading 
to the concept that this protein might be responsible for aiding in the replication in 
presence of such structures or by preventing their formation, therefore facilitating 
replication at telomeres. A recent study suggests that ATRX does not appear to possess 
G4-DNA unwinding activity and that it might overcome these impediments indirectly, 
perhaps by favouring the histone H3.3 deposition to maintain DNA in a B-form 
conformation (Figure 2) or by promoting a fork bypass via template switching [50, 51]. 
Furthermore, a potential consequence of loss of ATRX function is an increased frequency 
of G4-DNA, causing DNA damage [52]. So, it is likely that the presence of such structures 
in telomeric DNA favours the ALT phenotype by presenting a barrier to the replication fork, 
causing fork stalling, collapse and subsequent restart by the homologous recombination 
DNA-repair mechanism [51].  
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 Depletion of proteins or protein-complexes that are involved in HR and/or are 
required for replication fork restart like MRE11-RAD50-NBS1 (MRN complex), SMC5/6 
complex, MUS81 or the BLM helicase suppress telomeric recombination in ALT cells [53, 
54]. Particularly, the MRN complex functions includes DSB repair (via HR or NHEJ) and 
the restart of stalled replication forks [55] and, like ATRX, it co-localizes to telomeres 
during the S and G2 phases of the cell cycle [56]. Also, G-quadruplexes were found to be 
a preferred substrate for the MRX (MRN yeast homologue) complex-component MRE11 
[57]. The association of MRN complex with PML bodies (constituting the APBs) seems to 
be a requirement for ALT activity and likely constitutes the sites of telomeric 
recombination [21]. This data shows that the proteins in the MRN complex might have an 
important role in the ALT mechanism as they interact with ATRX, PML bodies and 
telomeres.  
 Recently, it was demonstrated that ectopic expression of ATRX in an ALT-positive 
cell line significantly reduced replication fork stalling, likely limiting the substrate for HR 
and downregulating ALT [51]. Also, the same authors had already revealed that ATRX 
interacts with endogenous MRN complex components in a direct manner during DNA 
replication, suggesting that this interaction is likely to play a direct role in facilitating this 
process [50]. Moreover, the re-expression of ATRX in ALT cell lines resulted in a dramatic 
redistribution of the MRN complex away from telomeric DNA and PML nuclear bodies 
[51]. Overexpression of a PML nuclear body component, Sp100, also showed 
sequestration of MRN components away from APBs leading to suppression of ALT [53]. 
This suggests that ATRX expression in a cell with the ALT phenotype may limit ALT by 
redistributing MRN away from sites of telomeric recombination. The fact that G4-DNA are 
a substrate for MRE11 raises the possibility that MRN directly cleaves these structures 
triggering DBS formation and HR [51]. 
 All the available data has allowed to propose that the lack of ATRX is linked to ALT 
by two main mechanisms, which can act independently or not: i) without this protein there 
is an increase in stalled replication forks due to G4-DNA structures that promote HR and 
ii) the redistribution of the MRN complex to APBs may also promote this DNA-repair 
mechanism.  
  ATRX loss promotes ALT in mesenchymal cells 
A recent study evaluated the effect of knocking down ATRX in fibroblasts and 
epithelial cells, to determine whether loss of this gene promoted the ALT mechanism [58]. 
They found out that ATRX depletion in epithelial cells does not promote ALT activation. 
However, in fibroblasts, ATRX knock down led to an increased ALT frequency [58].   
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Embryonic stem cells are known to have telomerase activity. However, 
mesenchymal stem cells express little or no detectable telomerase [59] and this may be 
the reason why these cells do not activate telomerase in a similar frequency to epithelial 
cells. This suggests that telomerase expression may be repressed by continuous 
chromatin-mediated repression at mesenchymal lineage. Another possible explanation 
may be that epithelial cells express proteins that mesenchymal cells do not and one or 
more of those might have a role in helping to overcome G4-DNA structures and/or 
chromatinization.  
Although ATRX loss promotes ALT, it seems it is not enough to activate this alternative 
mechanism, even in fibroblast cell lines. In a recent study, knocking down ATRX in 
fibroblasts was capable of activating ALT in ten of twelve cultures [58]; one of the six 
controls activated ALT. This leads to the concept that loss of ATRX is not enough to 
activate ALT and the presence of ATRX is not enough to avoid ALT. This data suggests 
that there is a missing link in this mechanism, which can be other protein(s) or (epi-) 
genetic changes that can interact with ATRX.  
  ATRX expression suppresses ALT 
 It has been proposed that ATRX acts as a tumor suppressor. A study conducted in 
telomerase-negative U-2 OS ALT cells, which are also null for ATRX, revealed that re-
expression of ATRX in these cells suppresses the ALT phenotype and, if that re-
expression is switched off, it is acquired again. However, if G-quadruplexes are stabilized 
(using pyridostatin), ALT suppression by ATRX is prevented. This study also revealed that 
this suppression is dependent on the histone chaperone DAXX as re-expression of ATRX 
in ALT cells concomitant with DAXX KO was not capable of suppressing the ALT 
phenotype [51]. 
 Another study, conducted in three different ALT mesenchymal cell lines that lack 
ATRX expression, showed that ATRX re-expression represses the ALT mechanism [58], 
even though the cells had to enter crisis before the ALT phenotype emerged. The 
explanation for this event, as referred before, might be the fact that ATRX facilitates 
replication and resolution of the G-quadruplex secondary structures, not allowing 
replication fork stalling, subsequent DSB formation and activation of the HR mechanism 
(the latter is a known hallmark of ALT). Another possible explanation is that ATRX helps in 
the formation of telomeric chromatin, not allowing the formation of DNA secondary 
structures like G-quadruplexes, therefore potentiating the normal mechanism of telomere 
replication, with no intervention by the HR-mediated repair of DNA. 
 Lastly, it is pertinent to say that, as the results of a recent study show, loss of 
ATRX also suppresses resolution of cohered telomeres as, in the absence of this protein, 
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the histone variant macroH2A1.1 binds to the poly(ADP-ribose) polymerase tankyrase 1, 
preventing it from localizing to telomeres and resolving cohesion (as cohesion resolution 
is the known function of this specific polymerase) [60]. The persistent cohesion that 
follows loss of ATRX thus promotes recombination between sister telomeres (T-SCE), a 
known ALT hallmark. This data suggests that this phenomenon indeed controls 
recombination in ALT cells and points to a role of ATRX in the ALT phenotype, in addition 
to its DAXX/H3.3 histone chaperone function. Even though this does not resolve the 
question of whether ATRX has an unmistakable role in activating ALT, the possibility is 
raised that the precondition of persistent telomere cohesion might favour activation of the 
ALT pathway over the upregulation of telomerase during tumorigenesis [60].  
 
Genome engineering 
 
 The capacity to engineer biological systems and organisms or to specifically alter 
genomes holds extreme potential for application in the areas of basic science, medicine 
and biotechnology. Per example, KO experiments have been one of the most informative 
approaches to unsolved problems or questions in science. Also, genome engineering 
techniques have been discovered and ameliorated to a point humanity would never have 
imagined, decades ago. These have even been extended to other purposes than the 
originally thought: imaging of specific genomic regions through genome engineering of 
specific cells/organisms would have never been possible without the discovery of proteins 
such as GFP (or more recently, CRISPR associated protein 9 (Cas9)) that occur naturally 
as they are expressed by certain species. These findings were thus readily converted in 
tools that might help solve the intrinsic questions that follow consciousness. 
  There are now several known programmable sequence-specific endonucleases 
that permit precise editing of endogenous genomic loci in a broad range of species. The 
discovery of these enzymes led to the arising of a number of genome editing technologies 
in the recent years, including zinc-finger nucleases (ZFN) [61-64], transcription activator-
like effector nucleases (TALEN) [64-68] and the RNA-guided Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) - Cas nuclease system [69]. The first 
two rely on a strategy of tethering endonuclease catalytic domains to modular DNA-
binding proteins for inducing targeted DNA DSBs at specific genomic loci. By contrast, S. 
Pyogenes Cas9 (component of bacterial CRISPR-Cas Type II) is a nuclease guided by 
small RNAs through base pairing with target DNA. The later represents the most recently 
and advantageous designed technology. Amongst Cas9 advantages over ZFN and 
TALEN are: the rapid customization (the enzyme can be easily retargeted to new DNA 
sequences by using a new pair of oligos encoding the 20-nt guide sequence), higher 
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targeting efficiency (contrasting with TALENs, that cleave non-specifically, SpCas9 
performs a blunt cut 3bp 5’ of the protospacer adjacent motif (PAM) sequence and the 
multiplex genome editing possibility (by co-delivering a combination of small guided RNAs 
(sgRNAs) to the cells of interest) [70].  
 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas) 
 
 Bacteria and Archaea are frequently exposed to stresses such as infection from 
bacteriophages and other foreign genetic elements. The constant exposure to this 
exogenous DNA often results in Horizontal Gene Transfer (HGT), which can be mediated 
by transduction, conjugation and transformation of mobile elements such as plasmids [71]. 
This exposure eventually forced microbes to establish an array of defence mechanisms 
that allow the cell to recognize and distinguish “foreign” from “self” DNA and to survive 
exposure to these invasive elements. Occasionally, they even thrive in hostile and 
competitive environments. These mechanisms maintain genetic integrity; yet occasionally 
allow exogenous DNA uptake and conservation of genetic material advantageous for 
adaptation to the environment [72]. 
 Bacteria possess multiple methods to regulate genetic flux and resist phage 
infection. These include the mutation or masking of cell surface receptors, restriction-
modification, abortive infection and the Clustered Interspaced Short Palindromic Repeats 
(CRISPR) systems [71] which is a widespread mechanism that equips bacteria with a 
sequence-specific heritable acquired immunity against viruses and plasmids [73].  
  History 
 In 1987, Ishino and his collaborators detected five 29 bp repeats with 32 bp 
spacers near the Inhibitor of apoptosis (Iap) gene of Escherichia coli [69]. This was the 
first time interspaced palindromic repeat sequences were observed. Following this, other 
reports appeared for Mycobacterium tuberculosis [74], Haloferax spp [75] and 
Archaeoglobus fulgidus [76]. Later, Mojica and co-workers determined structure and 
sequence similarity as well as phylogenetic distribution of those repetitive elements [77], 
showing that CRISPR arrays display a high degree of homology between phylogenetically 
distant species and a wide distribution in bacteria and archaea. 
 At first terminology was inconsistent but, to simplify, the name Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) was proposed by Ruud Jansen and 
collaborators [78]. The same authors identified the four genes closely located to the 
CRISPR array, which were termed CRISPR-associated (Cas) genes 1-4 [78], this being a 
crucial step in understanding the role of this system. 
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 Surprisingly, in 2005, three independent studies showed that spacers matched 
sequences of extrachromosomal origin, including phages, prophages and plasmids [79-
81]. In combination with detailed bioinformatics analyses of the Cas proteins, it was 
hypothesized that CRISPR/Cas systems provided an RNAi-like mechanism of resistance 
against invading genetic elements for bacteria and archaea [82, 83]. Direct evidence 
confirming this hypothesis was later provided by two studies; Barrangou et al. found that, 
after viral challenge, bacteria integrated new spacers derived from phage genomic 
sequences and, removal or addition of particular spacers, modified the phage-resistance 
phenotype of the cell [84]. Subsequently, Marraffini and Sontheimer showed that 
CRISPR/Cas systems can also prevent both conjugation and transformation of plasmids 
in Staphylococcus epidermidis [85]. 
  CRISPR components 
CRISPR Arrays: Repeats, Spacers and Leader Sequence 
 A single genome can harbour more than one CRISPR array and these vary in size. 
Within arrays, repeat sequences alternate with spacers [69]. Repeats are typically 
identical in length and base sequence amongst themselves [77]. They are normally 
between 23 and 47 bp in length and those of the same subtype share a consensus 
sequence [86].  
 Spacer sequences are frequently unique in a genome. A large number of spacers 
match sequences originating from extrachromosomal sources (such as bacteriophages or 
plasmids) [79-81], thus conferring the sequence-specific immunity against those. Their 
length can vary throughout an array and lengths up to 72bp have been reported [87]. 
Surprisingly, in some organisms, spacers matching sequences within their own genome 
are found. Their function is unknown but it has been proposed that they are accidentally 
incorporated [88].  
 The leader sequence is the final CRISPR array component, localizing upstream of 
the first repeat [78]. This is an AT-rich (200-500bp long) sequence and it includes the 
promoter necessary for transcription [89-91].  
 
Cas proteins 
 Located near the CRISPR array are the genes encoding Cas proteins [78]. These 
enzymes are necessary for the acquiring of new spacers and targeting of invading 
elements. CRISPR/Cas systems are generally classified into types I, II and III based on 
the phylogeny and presence of specific Cas proteins [86]. Cas1 and Cas2 are found 
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across the three types and Cas1 is considered the universal maker of these systems. 
Cas3, Cas9 and Cas10 are specific for types I, II and III, respectively [86].  	
  General mechanism   
 As referred, CRISPR represents a family of DNA repeats found in most archaeal 
(~90%) and bacterial (~40%) genomes [78, 92, 93]. It uses small non-coding RNAs for 
defence and functions together with Cas proteins. Its mechanism involves three phases 
(Figure 5): The first is the integration of short sequences from “foreign” genetic elements 
(known as spacers) into repetitive “self” genetic elements (known as CRISPR arrays). 
Then, these are transcribed and processed into small RNAs (crRNAs) by Cas proteins. 
Finally, a Cas protein complex together with crRNAs mediates targeting of the invading 
element, interfering with their nucleic acids [71].  
Figure 5 - Overview of CRISPR/Cas adaptive immunity. I – Adaptation: CRISPR arrays 
are composed of short repeats sequences derived from foreign invaders (spacers). Upon 
infection by a foreign element, part of its genome is incorporated into the leader end of the 
CRISPR array (which is adjacent to a cluster of Cas genes); II – crRNA generation: The 
CRISPRs are transcribed into pre-crRNAs that are then processed into mature crRNAs; III 
– Interference: The Cas protein-crRNA complex binds and degrades the target nucleic 
acid. Adapted from Richter, C. et. al 2012 [71].	
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  Type II systems 
 Type II CRISPR/Cas was first discovered in Streptococcus pyogenes [94] and it is 
characterized by the presence of Cas9 (besides Cas1 and Cas2 ubiquitous proteins), a 
protein containing two nuclease domains (RuvC-like and HNH) [86]. In this type of system, 
a short trans-encoded transcript (tracrRNA – trans-activating crRNA) is necessary for 
processing of the pre-crRNA into mature crRNA [94]. Cas9, in complex with the tracrRNA-
crRNA structure (that will be now on referred to as single-guide RNA (sgRNA)), binds the 
target dsDNA, creating a double strand break by cleaving the complementary and non-
complementary strands with its HNH- and RuvC- like domains, respectively [95]. Garneau 
and co-workers observed in vivo cleavage of dsDNA at a position 3 bp from the PAM 
sequence within the protospacer (the sequence that gives rise to the spacer) [96]. This 
sequence (5’-NGG-3’) seems to be of extreme importance in the affinity towards the target 
as cleavage of genomic sequences with mutated PAM is impaired in dsDNA [97]. Phages 
with PAM mutations have thus the ability to avoid targeting by type II systems. Moreover, 
complementarity between crRNA and target over a 13 bp stretch proximal to the PAM is 
required for interference with the nucleic acid, meaning that phages with mutations in this 
region of the protospacer might evade it [97]. The CRISPR/Cas9 genome engineering 
technique was thus derived from this specific type of prokaryotic defence system.  
  CRISPR/Cas9 applications  
 CRISPR was originally employed to “knock-out” target genes [95, 98] in various 
cell types and organisms. For this it is necessary to induct co-expression of the Cas9 
endonuclease and a sgRNA targeting a specific gene. The genomic target can be any ∼20 
nucleotide DNA sequence, provided that it is unmatchable (comparing to the rest of the 
genome) and is located immediately upstream of a PAM sequence. Once co-expressed, 
the Cas9 protein and the sgRNA form a riboprotein complex, allowing Cas9 to adopt an 
active DNA-binding conformation. This complex will then bind any genomic sequence with 
a PAM but the extent to which the sgRNA matches the target DNA determines whether 
the enzyme will cut. The end result of Cas9-mediated DNA cleavage is a DSB within the 
target DNA (∼3-4 nucleotides upstream of the PAM sequence) that can then be repaired 
by one of two DNA-repair mechanisms (HR or NHEJ), depending on the presence or 
absence of a template sequence, respectively. The first is the most active repair 
mechanism, capable of rapidly repairing DSBs. In most cases, this mechanism gives rise 
to small nucleotide insertions or deletions (InDels) in the target DNA which result in in-
frame amino acid deletions, insertions, or frameshift mutations. This leads to premature 
stop codons within the open reading frame (ORF) of the targeted gene and, ideally, result 
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in loss-of-function mutation of such gene. On the other hand, Homologous Recombination 
can be used to generate specific nucleotide changes (also known as “gene edits”), 
ranging from a single nucleotide change to large insertions. To achieve this, a DNA “repair 
template” containing the desired “edit” sequence must be delivered into the cell type of 
interest together with the sgRNA(s) and Cas9. The repair template must contain the 
desired edit as well as additional homologous sequence immediately upstream and 
downstream of the target (termed left & right homology arms) [99].  
 More recently, various modifications to the Cas9 enzyme have extended the 
applications of this technique: selectively activate or repress target genes [100], purify 
specific regions of DNA [101], image DNA in live cells using fluorescence microscopy 
[102] and even genome-wide screens [103]. Furthermore, the ease of generating sgRNAs 
makes CRISPR one of the most scalable genome editing technologies. 
 
Imaging DNA in live cells 
 In 2013, a repurposed nuclease-deactivated Cas9 (dCas9) had been used by 
Gilbert and collaborators to regulate endogenous gene expression by controlling the RNA 
polymerase activity or modulating promoter accessibility when fused with transcription 
factors [100]. The generation of a deactivated Cas9 (by mutationally inactivating its two 
nuclease domains) that could be fused to other molecules such as transcriptions factors 
or the GFP protein brought new possibilities for the application of the system. Following 
this, the same authors sought that the CRISPR system could serve as a universal and 
flexible platform for the dynamic imaging of specific genomic elements in living 
mammalian cells [102]. This stressed the possibility, amongst others, of using dCas9 
fused to the GFP protein and a sgRNA guiding to a telomeric repeat sequence to visualize 
and compare the telomeric lengths and observable appearance in living cancer cells. 	 	
  Limitations of CRISPR/Cas9 
  Each Cas9 ortholog has a unique PAM sequence. This does not totally limit the 
targeting range of this enzyme – in the human genome such target sites can be found on 
average every 9-12 bp [104, 105]. Another limitation of the CRISPR-Cas9 technique is the 
potential for off-target mutagenesis for a given guide sequence [105, 106]; however, they 
can be predicted and likely minimized by following general design guidelines [105], with 
the aid of bioinformatics.  
  Ethical challenges  
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 The simplicity of using the CRISPR/Cas9 system to engineer genomes in living 
organisms truly represents a new era in the fields of biology and genetics. 
However, several concerns regarding its ethics and biosafety have emerged in the past 
few years, especially since the publication of a paper reporting gene editing in human 
embryos [107].  Thenceforth, the editorial teams of both Science and Nature have written 
that the use of this technology for genome editing in human germline cells should be 
“addressed very seriously” and that “progressive policies should be developed/discussed”. 
Human embryo editing is thus a controversial theme among scientists; some countries 
have even banned the use of the CRISPR/Cas9 technology in humans. This implies that a 
framework for open discourse on this issue (both within the scientific community and 
publicly, regarding scientific and ethical social concerns) is urgently needed. The safety 
and efficacy issues regarding this technology must be investigated and understood before 
attempts at human engineering for clinical testing. Considerations include the possibility of 
off-target alterations as well as on-target events that have unintended consequences 
[108]. These discussions should be initiated rather sooner than later as they are crucial in 
order to lead society’s choices in this new era of biological/genetic engineering.  
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AIMS OF THE STUDY 
 
 The aim of this study was to take advantage of the recently designed genome 
engineering technology CRISPR/Cas9 and optimize its application in the imaging of 
genomic loci in living human cells.  
In particular, we aimed to produce a tool that allowed the visualization of telomeres 
through the targeting of a fluorescent protein complex (dCas9-EGFP) to telomeric repeats 
(by sgRNA) in Bon pancreatic neuroendocrine tumour cells. 
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METHODOLOGY 
 
Material 
  Plasmids 
 dCas9-EGFP, sgRNAs (sgTelomere and sgGAL4) and lentiviral (packaging and 
envelope-expressing) plasmids were commercially available (Addgene, Cambridge, USA). 
pSLQ1658-dCas9-EGFP (Addgene plasmid # 51023) and pSLQ1651-sgTelomere(F+E) 
(Addgene plasmid # 51024) were a gift from Bo Huang and Stanley Qi. pU6-sgGAL4-4 
(Addgene plasmid # 46916) was a gift from Stanley Qi and Jonathan Weissman. pMD2.G 
(Addgene plasmid # 12259) and psPAX2 (Addgene plasmid # 12260) were a gift from 
Didier Trono. pCMV-Tet3G Vector (Clontech Cat. No. 631335, Tet-On 3G Transactivator) 
was obtained as part of the Tet-On® 3G Inducible Expression System (with mCherry) 
(Clontech – Takara Bio, Mountain View, USA). 
  Cell lines 
 The two cell lines used in this work were available in the Ipatimup cell bank. 
Human embryonic kidney HEK293FT cells were used for lentiviral production by transient 
transfection. Bon cell line was used as it is originally derived from a human metastatic 
neuroendocrine pancreatic tumour [109] and represents a potential model for the study of 
the impact of ATRX depletion in the generation of the ALT phenotype. These cells were in 
three different conditions (WT, shRNA Control and shRNA ATRX – Knockdown (KD)). 
Control and KD were previously established in the lab.    
 
Methods 
  Bacterial culture and transformation 
 Bacteria were plated in Luria Broth (LB) agar with ampicillin (100 μ g/mL) 
overnight at 37ºC in an incubator. In the next morning, single colonies were isolated using 
a sterile pipette tip and inoculated in liquid LB media with ampicillin (100 μg/mL) (Sigma-
Aldrich, St.Louis, USA). Cultures were incubated for 12-18h in an orbital shaker incubator 
(Biosan, Riga, Latvia), at 37ºC. LB media with ampicillin without any bacterial inoculation 
was used as negative control. After bacterial growth, 500 µL of the overnight cultures 
were added to 500µL of 50% glycerol (Sigma) in a cryovial to create glycerol stocks 
stored at -80ºC. 
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 Clontech’s plasmid DNA was received in storage buffer (10 mM Tris-HCl (pH 8.0), 
1 mM EDTA (pH 8.0)). This plasmid DNA (0,5µL) was mixed with 50µL of E. coli 
competent cells in a microcentrifuge tube. The DNA was transformed in bacteria by the 
standard heat shock transformation protocol. Competent cells with plasmid DNA mixture 
were put on ice for 30 minutes and submitted to heat shock at 42ºC for 45 seconds in a 
thermomixer (Eppendorf, Hamburg, Germany). Following this, cells were put back on ice 
for 2 minutes. Competent cells (250µL) were then added to LB media and grown at 37ºC 
in an orbital shaking incubator for 45 minutes. After this, transformed cells were plated in 
LB agar plates with 100μg/mL ampicillin and incubated at 37ºC overnight. Following this, 
an overnight liquid culture was inoculated with a single colony and a glycerol stock was 
created, as described before. 
 All plasmids were posteriorly isolated and purified. First, bacterial cultures were 
grown from the glycerol stocks: a sterile pipette tip was used to inoculate the frozen 
bacteria into 100 mL of LB media that was then incubated at 37ºC with constant shaking 
for 12-16 hours. For isolation and purification, NZYMaxiprep (nzytech, Lisboa, Portugal) 
kit was used according to the manufacturer instructions.   
  Electrophoresis and Sanger sequencing. 
 Plasmid DNA size (kb) and sequence were confirmed by electrophoresis and 
Sanger sequencing, respectively. To linearize plasmids, 1μL (≅ 500ng) plasmid DNA was 
mixed with 15μL H2O, 2μL reaction buffer and 1μL restriction enzyme Hind III 
(ThermoFisher, Waltham, USA) was used to cut dCas9, Tet3G and pMD2.G; NheI 
(ThermoFisher) for psPAX2, sgGAL4 and sgTelomere. A 1% agarose gel was prepared 
by mixing 0,8g GRS agarose (Grisp, Porto, Portugal) with 80mL SGTB 1x Agarose 
Electrophoresis Buffer (Grisp). Loading samples were prepared by mixing 1μL glicerol 
and bromophenol blue Loading Buffer + Gel Red (Biotium, Fremont, USA) with 2,5μL 
DNA. 1kb Plus DNA Ladder (Invitrogen, Carlsbad, USA) served as ladder marker. 
Samples were loaded in the gel, which was run at 120V by 40 minutes.  
 Sequencing reaction was performed with the ABI Prism BigDye Terminator Kit 
(Perkin-Elmer, Foster City, USA) and the fragments were run in an ABI prism 3100 
Genetic Analyser (Perkin-Elmer). M13rev reverse primer (Sigma-Aldrich) , 5′-CAG GAA 
ACA GCT ATG ACC-3′ was used to sequence dCas9 and psPAX2 vectors. CMVfw 
forward primer (Eurogentec, Seraing, Belgium), 5’-GCT GTT TTG ACC TCC ATA GAA G-
3’ was used to sequence pMD2.G and Tet3G vectors. pcDNA4_6_CMV forward primer 
(Invitrogen), 5’-CATGAAGAATCTGCTTAGGG-3’ was used to sequence sgGAL4 and 
sgTelomere vectors.     
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  Cell culture 
 HEK293FT cells were cultured in Dulbecco’s Modified Eagle Medium High 
Glucose (Capricorn Scientific, Ebsdorfergrund, Germany) supplemented with 10% FBS 
(Capricorn), 1% Penicillin/Streptomycin (Capricorn) and 0,5% Fungizone (Capricorn). 
BON cells were cultured in Dulbecco’s Modified Eagle Medium/Nutrient F-12 Ham 
(Capricorn) supplemented with 10% FBS (Capricorn), 1% Penicillin/Streptomycin 
(Capricorn) and 0,5% Fungizone (Capricorn). For culturing Bon shRNA CTRL and shRNA 
ATRX, the media was maintained with 2ηg/mL puromycin (InvivoGen, San Diego, USA), 
to perform continuous selection of the cells containing the shRNAs. All cells were 
maintained at 37ºC in a 5% CO2 controlled environment. Both cell lines were tested for the 
presence of Mycoplasma. Upon reaching confluence, cells were trypsinized and seeded 
at the desired density in T25 flasks for growth, 6-well plates for transfection or 24-well 
plates for lentiviral transduction.    
  Protein extraction and Western Blot 
 Cells were lysed for 15 min at 4ºC using Radioimmunoprecipitation Assay (RIPA) 
buffer (1% NP-40 in 150 mM NaCl, 50 mM Tris (pH 7.5), 2 mM EDTA) containing 
phosphatase and protease inhibitors. Cells were then collected by scraping and pelleted 
by centrifugation for 5 minutes at 14000 rpm and 4°C, to remove cell debris. The 
supernatant, which contained the fraction of cytoplasmic proteins, was recovered and 
stored at -20ºC. Proteins were quantified using a modified Bradford assay (Bio-rad, 
Hercules, USA), at 650 nm. Protein samples (40 µg) were separated in 10% SDS/ PAGE 
gels and transferred to Hybond ECL membrane (GE Healthcare, Little Chalfont, UK). Anti-
ATRX rabbit (Sigma-Aldrich) was used as primary antibody. Goat anti-rabbit secondary 
antibody (Santa Cruz Biotechnology, Dallas, USA) was conjugated with peroxidase and 
visualized by ECL solution. Membranes were re-stained with a goat polyclonal anti-actin 
(Santa Cruz Biotechnology) antibody for protein loading control. All antibodies were used 
in 1:2000 dilutions. 
CRISPR/Cas9 (imaging)   
  Lentiviral production 
 HEK293FT cells were cultured in Dulbecco’s Modified Eagle Medium High 
Glucose (Capricorn) supplemented with 10% Tet-System Approved FBS (Clontech), 1% 
Penicillin/Streptomycin (Capricorn) and 0,5% Fungizone (Capricorn) in 100mm tissue 
culture dishes until 70-80% confluence. The following mixtures were prepared, per plate, 
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and incubated for 15 minutes each: I. 8µg interest vector (dCas9, Tet3G, sgTelomere, 
sgGAL4) + 6µg lentiviral packaging plasmid (psPAX2) + 2µg VSV-G envelope expressing 
plasmid (pMD2.G) in 300µL OptiMEM (ThermoFisher) ; II. 16µL Lipofectamine 2000 
(ThermoFisher) in 300µL OptiMEM. After this, both were mixed and incubated for 30 
minutes. Meanwhile, media of HEK293FT cells was removed and 3mL of OptiMEM 
added. The plasmids were then added drop wise into the cells and this mixture was 
incubated for 3h, at which point 10mL of DMEM+10% Tet System Approved FBS were 
added. In the next morning, media was changed and cells were incubated at 32,5ºC for 
the rest of the protocol. Supernatants containing lentivirus were collected at 36, 48 and 
72h post-transfection and kept at 4ºC. Supernatants were then filtered with a 0,45µm filter 
and 1mL of each was collected and stored at -80ºC. Virus were then concentrated using 
Amicon Ultra Centrifugal Filter Units (Merck Milipore, Billerica, USA) at 1600g for 30 
minutes. Concentrated viruses were stored at -80ºC.  
  Lentivirus titration by qRT-PCR 
 Supernatants (150µL) were measured for lentivirus titer using Lenti-X qRT-PCR 
Titration Kit (Clontech). It is composed by a quick RNA purification step (Nucleospin RNA 
Virus Kit and respective protocol) before quantifying the number of lentiviral genome 
copies using qRT-PCR and SYBR® technologies. The protocol in the kit was executed 
according to manufacturer instructions.   
  dCas9-EGFP/Tet-On 3G lentiviral transduction 
 Bon WT cells stably co-expressing dCas9-EGFP and Tet-On 3G transactivator 
(Tet3G) were generated by lentiviral transduction. Approximately 10,000 Bon WT cells 
were plated into 3 wells of 24-well plates (20 to 30% confluence) 12-18h before infection. 
Each well contained 0,5mL complete growth medium (supplemented with 10% Tet 
System Approved FBS. Concentrated lentiviral stocks (dCas9-EGFP and Tet 3G) were 
thawed, combined at a 1:1 ratio and added to the cells. Transduction was done overnight 
at 37ºC and medium was supplemented with polybrene (8µg/mL) (Sigma). In the next 
morning, virus/polybrene-containing media was discarded and replaced with fresh 
complete medium (10% FBS). After 36h, medium was replaced again and doxycycline 
(Sigma) was added to one of the transduced wells at a concentration of 100ng/mL for 
inducing high expression of dCas9-EGFP. Cells were incubated for 12-24h, at which 
point, the ZOE fluorescent cell imager (Bio-Rad) was used to determine if dCas9-EGFP 
was properly localized in the cell’s nucleus (as it contains NLS function). After being 
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confluent, cells were trypsinized and passaged to a 6-well plate to further visualization and 
to T25 flasks to freeze.  
  sgRNA lentiviral infection 
 Approximately 4,000 cells were plated into a 8-well chambered coverglass 12-18h 
before infection. Each well contained 0,4-0,5mL DMEM-F12. Concentrated lentiviral 
stocks (sgTelomere and sgGAL4) were thawed and added to the cells. Transduction was 
done overnight at 37ºC and medium was supplemented with polybrene (8µg/mL) (Sigma). 
In the next morning, virus/polybrene-containing media was discarded and replaced with 
fresh complete medium. 48h post-transduction, the cells were observed with ZOE 
fluorescent cell imager. 
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RESULTS 
 
  Purified plasmidic DNA quantification 
 Plasmid stocks were expanded and purified. DNA quantity in the resulting products 
was 697,3ηg/µL for sgTelomere; 529,4ηg/µL for pMD2.G; 453,5ηg/µL for Tet3G; 
430,5ηg/µL for psPAX2; 812,4ηg/µL for sgGAL4 and 164ηg/µL for dCas9-EGFP (Table 
1). All DNA was resuspended in 200-400µL of DNAse/RNase-free sterile H2O before 
quantification.  
 
Sample ID ηg/µL A260 A280 260/280 260/230 
sgTelomere 697,3 13,946 7,517 1,85 2,29 
pMD2.G 529,4 10,588 5,759 1,84 2,33 
Tet3G 453,5 9,070 4,860 1,87 2,29 
psPAX2 430,5 8,609 4,615 1,87 2,32 
sgGAL4 812,4 16,248 8,647 1,88 2,33 
dCas9-EGFP 164 3,260 1,790 1,83 2,19 
 
Table 1 – Plasmid DNA quantification. Quantities in ηg/µL. A260/280 ratio accounts for 
assessment of nucleic acid purity. As these values are close to 2, it is inferable that the 
data is reliable and samples are not contaminated.  
  Plasmid electrophoresis 
 After obtaining the purified plasmid DNA, it was linearized by digestion with one of 
two (HindIII and NheI) restriction endonucleases and ran in a 1% agarose gel to confirm 
vector size (bp). As expected, pMD2.G size was 5,8 Kb (well 2), sgTelomere was 8Kb 
(well 3), sgGAL4 was 8Kb (well 4), psPAX2 was 10Kb (well 5), Tet3G was 7,1Kb (well 6) 
and dCas9-EGFP was 11Kb long (well 7). The traces of DNA seen in the top of wells 2 
and 3 are probably the result of an incomplete digestion by the restriction enzyme and/or 
the appearance of secondary structures of plasmidic DNA, creating extra bands (Figure 
6). 
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Figure 6 – Plasmid electrophoresis gel. 1 – Marker, 2 – pMD2.G, 3 – sgTelomere, 4 – 
sgGAL4, 5 – psPAX2, 6 – Tet3G, 7 -  dCas9-EGFP.  
  Plasmid sequencing 
 The next step was to confirm vector sequence. Sequencing reaction was 
performed as described before and the plasmid DNA sequence was compared with the 
ones provided by the suppliers (Addgene, Clontech). As expected, all sequences matched 
up and no mutations were detected (Figure 7). 
  
Figure 7 – An example of a part of a sequence (dCas9-EGFP) is shown. See other 
vector’s partial sequences in Supplementary Figures. 	
  Transfection with Lipofectamine 2000   
 HEK293FT transfection with the packaging (psPAX2), envelope-expressing 
(pMD2.G) and interest (dCas9-EGFP, Tet3G, sgGAL4 or  sgTelomere) vectors was 
performed in order to obtain four different types of lentiviral particles (corresponding to the 
four interest DNA vectors). The first time, only the exact necessary amount of lentivirus to 
transduce two wells of a 24-well plate containing Bon WT cells was produced. We infected 
these cells with only the Tet3G lentivirus and immediately tried to perform selection using 
 1       2        3         4         5        6         7 
  
 
 
    12kb 
 
      5kb 
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the G418 antibiotic (Sigma) (from which Tet3G confers resistance). All other lentivirus 
were stored at -80ºC. 15 days after starting selection all cells were dead, meaning that we 
hadn’t been able to perform selection and we had lost all Tet3G lentivirus. For this reason, 
we decided to produce another batch of lentivirus by transfection. Once again, all products 
were stored at -80ºC. By this time, we had resolved that we would do (simultaneous) co-
transduction of Bon cells with Tet3G and dCas9-EGFP lentivirus in order to be able to 
identify the infected cells by fluorescence microscopy (only in the presence of the two 
vectors the cells will produce nuclear fluorescence) instead of by selection. 
  Lentiviral titration – Quantitative RT-PCR 
 A small part of the Tet3G and dCas9-EGFP lentiviral samples obtained in the 2nd 
transfection experiment was used to perform quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR), which was the chosen method to titrate the lentiviral samples. This 
provided us the information about the presence and quantity of the lentiviral particles in 
the two samples, comparing with the standard provided by the commercial kit. As 
observed in the amplification plot (Figure 9), we obtained the amplification curves for five 
standards (in grey) as well as for the two produced lentiviral samples (Tet3G in blue, 
dCas9-EGFP in green). The established threshold was 0,040395, which defined the CT 
values for the analysed samples.  
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Figure 9 – qRT-PCR amplification plot. In grey, the five standards used to produce the 
standard curve. In blue, the Tet3G sample. In green, the dCas9-EGFP sample. All 
samples were duplicated. Threshold was 0,040395. 
 
 We also obtained the standard curve and melt curve plots (Figure 10). The first 
provided us data about the efficacy of the reaction, which was 97,9% (meaning that it was 
a very efficient reaction, as this value should be between 90-110%). Also, the slope value 
(-3,374) shows a concordant result with the efficacy. The melt curve plots provided the 
information about the quality of the data. The fact that all melt curves (five standards and 
two samples) are in the same spectrum and always consist of a unique peak indicates 
that the data is reliable.   
 
Figure 10 – Lentiviral titration by quantitative RT-PCR. (A) Standard Curve. In grey, the 
five standards. In blue, the Tet3G sample. In green, the dCas9-EGFP sample. The x-axis 
corresponds to the quantity of lentivirus in the sample. The y-axis corresponds to the CT 
value of the various samples. Curve slope was -3,374. Efficacy was 97,9%; (B) Melt 
Curve. All seven samples (and duplicates) produced one single peak in similar 
temperature values. 
 
A	 B 
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 Lastly, we obtained the data referring to the quantity (in units) of lentivirus in all 
samples and the cycle threshold (CT) values. Standards 1, 2, 3, 4 and 5 were successive 
dilutions of the lentiviral standard provided by the kit, being the quantity of lentivirus in 
each 5E-07, 5E-08, 5E-09, 5E-010 and 5E-11 units, respectively. Its CT values means 
were 9,27; 11,99; 16,54; 19,28; 22,50, respectively. For our samples, Tet3G mean 
lentiviral quantity was 1,10E-10 units and mean CT was 21,51. For dCas9-EGFP, mean 
lentiviral quantity was 2,19E-09 units and mean CT was 17,13 (Table 2). Here, we 
confirmed what we could already observe in the amplification plot: dCas9-EGFP sample 
had 10-fold more lentiviral units than the Tet3G one.  
 
Table 2  - Quantity of lentiviral particles and CT values for the standards and Tet3G and 
dCas9-EGFP samples.  
  Tet3G/dCas9-EGFP lentiviral co-transduction 
 We performed co-transduction of Bon WT cells with Tet3G and dCas9-EGFP 
lentivirus in 24-well plates, overnight. 48h later, a small percentage of the cells had 
nuclear fluorescence. As Tet3G codes for an activator of the TRE3G promoter present in 
the dCas9-EGFP plasmid and this activation only occurs in the presence of doxycycline 
(Tet-On inducible expression), we maintained transduced cells in two conditions: dCas9 
(transduced cells in normal media) and dCas9+Dox (transduced cells in media containing 
100ηg/mL Doxycycline). We took pictures of all wells using two conditions (Brightfield and 
Green fluorescence) of the ZOE fluorescent cell imager (Figure 11). Compared to the 
Control Bon WT cells (CTRL) where there is only random fluorescence in the media or in 
auto-fluorescing cells, the co-transduced cells (dCas9) exhibit points of green 
 
Well Sample Name Reporter Cт Cт Mean Cт SD Quantity Quantity Mean Quantity SD 
B4 Std1 SYBR 9,107636452 9,274354935 0,235776216 5E-07   
B5 Std1 SYBR 9,441074371      
C4 Std2 SYBR 11,84287167 11,9901638 0,208303213 5E-08   
C5 Std2 SYBR 12,13745689      
D4 Std3 SYBR 16,38324928 16,54104614 0,223157108 5E-09   
D5 Std3 SYBR 16,69884109      
E4 Std4 SYBR 18,81335449 19,27684021 0,65546912 5E-10   
E5 Std4 SYBR 19,74032784      
F4 Std5 SYBR 22,7010994 22,50058174 0,28357479 5E-11   
F5 Std5 SYBR 22,30006409      
         
         
B6 Tet_1x SYBR 21,57520676 21,51176071 0,089724906 1,05144E-10 1,09899E-10 6,72542E-12 
B7 Tet_1x SYBR 21,44831657   1,14655E-10   
B8 dCas9_1x SYBR 17,11772919 17,1286087 0,015387309 2,20266E-09 2,18643E-09 2,29601E-11 
B9 dCas9_1x SYBR 17,13949013   2,17019E-09   
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fluorescence that seem to be specifically localized in the nucleus of the cells. These are in 
little number, which indicates that the lentivirus transduction might not have been of great 
efficacy. In the presence of doxycycline, there is a notorious difference in the number of 
fluorescent nucleus, indicating higher expression of  the dCas9-EGFP protein complex.  
 
Figure 11 – Tet3G/dCas9-EGFP lentiviral co-transduced cells in a 24-well plate. Pictures 
taken in Brightfield and Green Fluorescence (488nm) conditions. CTRL are non-
transduced Bon WT cells. dCas9 are transduced Bon WT cells in normal media. 
dCas9+Dox are transduced cells in media containing Doxycycline.  
 
 As we couldn’t expand the cells because of a contamination, we recurred to our 
frozen lentivirus samples and repeated the experiment. We visualized and photographed 
fluorescence in 6-well plates (Figure 12). The same as in Figure 11 was observed as co-
transduced cells exhibited green fluorescence, being this effect more evident in those 
cultured with doxycycline. This indicated that the second experiment had been successful, 
although the efficacy seemed to remain low.  
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Figure 12 – Tet3G/dCas9-EGFP lentiviral co-transduced cells expanded to a 6-well plate. 
Pictures taken in Brightfield and Green Fluorescence (488nm) conditions. CTRL are non-
transduced Bon WT cells. dCas9 are co-transduced Bon WT cells in normal media. 
dCas9+Dox are co-transduced cells in media containing Doxycycline. 
 
 This time, we were able to expand transduced cells to T25 flasks, at which point, a 
part of those were frozen. Pictures were taken by merging the brightfield and green 
flourescent conditions, providing a better visualization of the fluorescence (Figure 13). The 
difference between control cells and co-transduced remained observable and was evident 
when doxycycline was added. 
 
Figure 13 - Tet3G/dCas9-EGFP lentiviral co-transduced cells seeded in T25 flasks. 
Pictures taken in Merge (Brightfield + Green Fluorescence) condition. CTRL are non-
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transduced Bon WT cells. dCas9 are co-transduced Bon WT cells in normal media. 
dCas9+Dox are co-transduced cells in media containing Doxycycline.  
 
 We then tried to select clonal cells stably expressing Tet3G/dCas9 by two 
methods, simultaneously: serial dilutions and antibiotic resistance. In the various dilutions 
trials, we could not isolate a single fluorescent colony of cells originating doubtlessly from 
a unique cell. We tried to perform selection with media containing 500 ηg/mL of puromycin 
as the dCas9-EFDP vector confers resistance to this antibiotic but all cells died after 15-
17 days.   
 We thus sought to experiment transducing the Bon cells with a different ratio of 
lentivirus, which could improve the efficacy of the process. The remaining stored amount 
of lentiviral samples allowed us to infect Bon WT cells with a 2:1 ratio of Tet3G/dCas9-
EGFP lentivirus. As before, cells were expanded to T25 flasks, at which point we took 
pictures (Figure 14). Comparing to the previously tested 1:1 lentiviral ratio, there were no 
observable differences in the localization or intensity of the fluorescence. It remained low 
and in little quantity, again showing apparent low transduction efficacy. 		 	  
 
Figure 14 - Tet3G/dCas9-EGFP 2:1 lentiviral co-transduced cells seeded in T25 flasks. 
Pictures taken in Merge (Brightfield + Green Fluorescence) condition. CTRL are non-
transduced Bon WT cells. dCas9 are co-transduced Bon WT cells in normal media. 
dCas9+Dox are co-transduced cells in media containing Doxycycline.  
  sgRNA lentiviral infection 
 As we didn’t have the time to try to select these cells, we decided to transduce all 
the non-selected dCas9/Tet3G previously infected cells that were being cultured (with 
both 1:1 and 2:1 lentiviral ratio) with the sgRNAs (sgTelomere and sgGAL4). The result 
was inconclusive as we were not able to identify points of fluorescence specific to the 
nucleus of the cells that would indicate the presence of telomeres. 
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Figure 15 - Tet3G/dCas9-EGFP/sgRNA lentiviral co-transduced cells seeded in 8-well 
plate. Pictures taken in Green Fluorescence condition. CTRL WT are non-transduced Bon 
WT cells. CTRL dCas9 are Tet3G/dCas9 transduced cells. dCas9 + sgTel are 
Tet3G/dCas9/sgTelomere transduced cells. dCas9 + sgGal4 are Tet3G/dCas9/sgGal4 
transduced cells. 
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DISCUSSION 
 
 
 In this project, we aimed to establish a tool for the visualization of specific genomic 
loci (in this case telomeres) in living cells, without any kind of treatment or global DNA 
denaturation, by a CRISPR/Cas9 method where the Cas9 protein is deactivated (dCas9) 
and coupled to a Green Fluorescent Protein. This approach thus preserves the spatial 
relationships of the genetic elements, which is crucial for understanding the organization 
of the genome and its association with gene expression. We also wanted to compare the 
characteristics (type of fluorescence: its spatial localization, size, intensity and number of 
puncta) between different genetic conditions of the Bon cell line (WT, shRNA Control and 
shRNA ATRX).  
 Our approach to this aim was to produce lentivirus containing the necessary DNA 
for the Bon cells to express dCas9-EGFP and the interest sgRNAs and infect Bon cells 
with such lentivirus. Four types of lentivirus were generated, containing dCas9-EGFP 
(coding for a deactivated Cas9 protein coupled to and enhanced GFP), Tet3G (a vector 
coding for a protein that ligates dCas9 promoter and positively regulates its expression in 
the presence of doxycycline), sgTelomere (a single-guide RNA targeting telomeric 
repeats) and sgGAL4 (a single guide RNA with no known target in the human genome, to 
serve as control). Afterwards, we sought to establish a stable cell line expressing both 
Tet3G and dCas9 proteins, by selection, so that we could further infect these cells with the 
sgRNAs and observe the telomeric fluorescence. 
 Our initial results in the preparation of the vectors were as expected. The purified 
plasmid DNA was analysed for its size and sequence and this data was concordant with 
the information provided by the suppliers (Addgene and Clontech).  
 In this work it was not possible to attain our ultimately goal due to technical 
difficulties that affected some phases of the process. Regarding the CRISPR/Cas9 data, it 
is not conclusive but it opens the possibility of discussing the explanations for the 
observed events. As seen in Figure 13, Control (non-infected) cells are different from the 
infected ones. The fluorescence in the first ones is random and mostly located in what 
seem to be dying/dead cells or other particles in the media – autofluorescence. The 
Tet3G/dCas9 infected cells, on the other hand, exhibit blurs of fluorescence that are 
located in living cells, as we can see in the merged pictures (Figures 13 and 14), which is 
concordant with what is seen in the literature [102, 110, 111]. However, the fluorescent 
foci were in small number throughout the area of the flasks and were mostly located in 
cells that had a rounded format, contrasting with the adherent cells with a flattened format. 
This indicates that the infection process was successful but its efficacy low, drawback 
probably related to the processes of transfection and/or transduction. 
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 In the tentative to quantify and normalize the transfection experiments we have 
done quantification of the lentiviral load by qRT-PCR. Nevertheless the transfection 
process was not fully controlled as the quantitative RT-PCR protocol only provided data 
about the presence of lentiviral-specific sequences in the samples and not about its 
functionality. This means that the qRT-PCR analysis does not give indication about the 
percentage of lentivirus containing the DNA inserts of interest. Also, we could not be sure 
if they were correctly assembled and capable of successfully infecting the cells. Although 
we found sufficient quantity of lentivirus for transduction in the two analysed samples, the 
percentage of functional ones was thus unknown. Also, importantly, the qRT-PCR data 
indicated that the Tet3G lentiviral solution was 10 times less concentrated than the dCas9, 
as seen in Table 2.  
 Figures 11, 12 and 13 indicate that the transduction process was not of great 
efficacy. As referred, the fluorescent foci seen in these photographs are in small quantity 
and appear to be weak indicating that, while some cells might have been successfully 
infected, these represent a small percentage. These results could be related to a number 
of factors apart from the fact that the lentiviral production by transient transfection could 
have not been functional, as referred previously. As the Tet3G lentiviral solution was 10-
fold less concentrated comparing to dCas9 and as it is necessary that the two lentivirus 
are incorporated into the cells to produce fluorescence (the cells are co-transduced), the 
ratio of both lentivirus used in the transduction experiment was not intuitive and had to be 
optimized. We tried both 1:1 and 2:1 (Tet3G:dCas9) ratios (Figures 13 and 14, 
respectively) but no striking difference were observed between those two conditions. 
Nevertheless, a deeper analysis to this question should be done in future attempts to 
optimize this method in Bon cells and other ratios between the lentiviral solutions must be 
essayed. The dCas9 vector contains an inducible TRE3G promoter, meaning that the 
dCas9 protein expression is very strongly induced by the ligation of a Transactivator 
(Tet3G) protein to its promoter, in the presence of doxycycline. For this reason, we tried to 
stimulate the expression of dCas9 by adding doxycycline in two different concentrations: 
100 ηg/mL (Figure 13) and 200 ηg/mL (data not shown). This experiment was also 
inconclusive, as there were no significant differences between the two. In fact, 100 ηg/mL 
should be more than enough to immensely stimulate fluorescence [102]. 
 Throughout the entire experiment, it was only possible for us to use the ZOE 
Fluorescent Cell Imager in order to obtain the fluorescent cell imaging.  This means our 
observations were limited by the characteristics of this specific microscope. As it only 
allowed us to observe cells in one magnification and its background signal was always 
high, this represents a great limitation to our work.    
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 There is little information in the literature regarding the transduction of Bon cells 
with lentivirus. The intrinsic availability of these cells to transfection and transduction of 
lentivirus can also be an important factor to explain the low efficacy of the process. 
Although we didn’t observe massive cell death upon infection, it might not be intuitive to 
successfully infect these cells. Existing experiments in this field of research (imaging 
genomic elements in living cells by CRISPR/Cas9) are mostly conducted in the RPE cell 
line [102, 110]. 
 Afterwards, we tried to perform selection of infected Bon cells by the serial 
dilutions and antibiotic resistance methods. Both methods were unsuccessful, mostly 
likely due to the low efficacy of the transduction protocol. The little number of successfully 
infected cells producing fluorescence likely explains the fact that the cells didn’t survive 
the antibiotic selection. This experiment was performed in 6-well plates, which cannot 
contain a large number of cells. For this reason, if there were cells surviving after the 15-
17 days period of selection, they would be in very small number and probably couldn’t 
form new colonies in order to regrow. Regarding the serial dilutions method, we weren’t 
able to isolate, identify and plate a single fluorescent cell, as these cells were in such 
small percentage.  
 We lastly tried to infect the bulk population of cells, non-selected, with the sgRNAs, 
hoping that we could generate an example of what would be the targeted fluorescence to 
the telomeres in the nucleus, as seen in the literature [102]. Our result was inconclusive, 
as we could not see specific nuclear fluorescence in any of these cells. This is most likely 
explained by the fact that cells were plated in 8-well chambered coverglass, which also 
cannot contain a sufficient number of cells. As these cells were not stably expressing 
Tet3G/dCas9, the lack of fluorescence was not striking. 
 As our goals were not fully attained, we intend to continue trying to establish this 
tool by troubleshooting the whole process. There are various possible approaches to this 
problem in the future. We can try to directly transfect (instead of infecting with lentivirus) 
the cells with the Tet3G and dCas9 vectors to see if the cells successfully incorporate 
those vectors and produce a clear fluorescence signal that allows us to select them. Also, 
it might be promising to try to better control the processes of producing the lentivirus and 
infecting the cells in order to know if other ratios/quantities of lentivirus should be used.  
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CONCLUSIONS 
 
 
 We confirmed the capability of Bon cells to produce fluorescence by infecting them 
with lentivirus containing Tet3G and dCas9 vectors, even though the efficacy of the 
process was low. Following that, we tried to optimize this protocol in order to be able to 
produce telomeric-specific fluorescence. As this was unsuccessful, we will continue trying 
to establish this tool by troubleshooting the entire experiment and try again with a higher 
number of conditions and controls.   
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
Figure 1 – Partial sequence of Tet3G vector. 
 
 
Figure 2 – Partial sequence of psPAX2 vector 
 
 
Figure 3 – Partial sequence of pMD2.G vector. 
 
 
Figure 4 – Partial sequence of SgTelomere vector. 
 
 
Figure 5 – Partial sequence of sgGAL4 vector. 
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Figure 6 – Western Blot for the ATRX protein in Bon cells. 1 – Marker, 2 - Bon WT, 3 – 
Bon shRNA CTRL, 4 – Bon shRNA ATRX. As our secondary objective was to visualize 
and compare telomeric lengths in various Bon cells with different genetic backgrounds 
(WT, shRNA CTRL and shRNA ATRX), we performed Western Blot to confirm the KD of 
the ATRX protein in the latter type of cell. Indeed, the resulting membrane showed us that 
the KD was successfully established and ready for further experimenting as the bands in 
the membrane at ≈280kDa (the ATRX protein size) are much weaker in the shRNA ATRX 
well, compared to WT and shRNA CTRL.  
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